We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Insmed Inc (INSM) Com Stock USD 0.01

Sell:$21.94 Buy:$21.98 Change: $0.28 (1.26%)
Market closed |  Prices as at close on 20 January 2022 | Switch to live prices |
Change: $0.28 (1.26%)
Market closed |  Prices as at close on 20 January 2022 | Switch to live prices |
Change: $0.28 (1.26%)
Market closed |  Prices as at close on 20 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.

Contact details

700 US Highway 202/206
United States
+1 (908) 9779900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.63 billion
Shares in issue:
118.37 million
United States
US dollar

Key personnel

  • William Lewis
    Chairman of the Board, President, Chief Executive Officer
  • Sara Bonstein
    Chief Financial Officer
  • Roger Adsett
    Chief Operating Officer
  • Michael Smith
    Senior Vice President, General Counsel
  • John Soriano
    Chief Compliance Officer
  • Martina Flammer
    Chief Medical Officer
  • S. Nicole Schaeffer
    Chief People Strategy Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.